Introduction
============

Pulmonary hypertension is a common complication of pulmonary parenchymal diseases. Its presence is associated with a poor prognosis in patients with severe chronic obstructive pulmonary disease (COPD) \[[@B1],[@B2]\] and cystic fibrosis \[[@B3],[@B4]\]. Pulmonary hypertension is not uncommon among patients awaiting lung transplantation, so this situation is frequently dealt with during surgical or diagnostic procedures. In these situations, vasodilator and inotropic drugs, mainly low-dose dobutamine, are usually used in order to maintain hemodynamic stability. However this approach may have a detrimental effect on gas exchange \[[@B5]\].

Recently, inhaled nitric oxide (INO) in combination with oxygen has been used successfully to improve oxygenation and pulmonary hemodynamics in patients with COPD and acute respiratory distress syndrome \[[@B6]\]. However, the hemodynamic effects of a combination therapy with nitric oxide (NO) and low-dose dobutamine in patients with severe obstructive lung disease and pulmonary hypertension have not yet been addressed.

In order to establish the preliminary bases for this therapeutical approach we investigated the acute hemodynamic effects of INO, dobutamine, and the combination of the two in a group of patients with mild to moderate pulmonary hypertension secondary to severe airway disease.

Materials and methods
=====================

Subjects
--------

The study population was selected from among patients with end-stage pulmonary disease secondary to airway disease and pulmonary hypertension (with a mean pulmonary arterial pressure \>20 mmHg) who were evaluated for lung transplantation at the University of Rome hospital \'La Sapienza\'. Eight patients suffered from cystic fibrosis, nine from bronchiecta-sis, and 11 from COPD. The demographic and clinical data are summarized in Table [1](#T1){ref-type="table"}. All patients required continuous low-flow oxygen therapy and were being treated with inhaled beta~2~-adrenergic drugs (albuterol 600--1200 μg/day), prednisone (5--10 mg/day), and methylxanthines (theophylline 450--900 mg/day). Ten patients were treated with digoxin (0.25 mg/day) and furosemide (20--40 mg/day).

###### 

Demographic and clinical characteristics of the study population (28 patients)

  Characteristic         Mean (± SD)
  ---------------------- -------------
  Age (years)            38 ± 18
  Sex (M/F)              10/11
  Height (cm)            161 ± 12
  Weight (kg)            56 ± 19
  FVC (% predicted)      44 ± 12
                         28 ± 26
  FEV~1~ (% predicted)   
  TLC (% predicted)      99 ± 26
  RV (% predicted)       208 ± 67

FVC, forced vital capacity; FEV~1~, forced exhaled volume in 1 s; RV, residual volume; TLC, total lung capacity.

Evaluation of the patients included taking a clinical history, undertaking a physical examination, administering a chest X-ray, and monitoring by echocardiography. None of the patients had a history of systemic hypertension, valvular or ischemic heart disease. Pulmonary function tests were undertaken with a Med Graphics System 1085 (Medical Graphics Corp., St Paul, MN, USA) according to American Thoracic Society standards \[[@B7]\]. Functional residual capacity was measured by plethysmography; total lung capacity and residual volume were calculated using standard formulae (Table [1](#T1){ref-type="table"}). All data are reported as a percentage of the predicted normal value \[[@B8]\]. At echo-Doppler evaluation, all patients had normal left ventricular function, but mild to moderate right ventricular dilation was found in 10 patients. Tricuspid regurgitation was present in 23 patients but only in three was it more than trivial.

All patients were in a stable hemodynamic condition and were included in the study protocol after informed consent. The protocol was approved by the institutional review board for human studies.

Hemodynamic study
-----------------

All patients underwent a complete hemodynamic evaluation such as that required for routine screening prior to lung transplantation at the University of Rome hospital. Under local anesthesia a 7F Swan-Ganz triple lumen thermodilution catheter was inserted through the femoral vein and was positioned in the pulmonary artery. A polyethylene catheter was introduced into the radial artery. Transducers were referenced 5 cm below the sternal angle in the supine position. Right atrial pressure (central venous pressure, CVP), mean pulmonary arterial pressure (MPAP), mean pulmonary artery occluded pressure (PAOP), and mean systemic arterial pressure (MAP), were measured as the average of four respiratory cycles. Transpulmonary gradient (TPG) was defined as MAP-PAOP. Cardiac output was measured in triplicate by thermodilution. Cardiac index, systemic vascular resistance index (SVRI) and pulmonary vascular resistance index (PVRI) were calculated using standard formulae.

Samples of arterial and mixed venous blood were analyzed for oxygen pressure, carbon dioxide pressure, and pH using a blood gas analyzer (Instrumentation Laboratory Model 1300; Milan, Italy), which was calibrated with a proper gas mix with oxygen concentration of 90%.

Anatomic shunt/venous admixture effect (*Q*~s~/*Q*~t~) was calculated according to Cotes \[[@B9]\], using the mass balance equation:

*Q*~s~/*Q*~t~(%) = CcO~2~-CaO~2~/CcO~2~-CvO~2~

where CcO~2~ is capillary content of O~2~, CaO~2~ is arterial content of O~2~, and CvO~2~ is mixed venous content of O~2~. Arterial, capillary, and mixed venous oxygen content were calculated as follows:

content = (Hb × 1.39 × % saturation) + (PO~2~ × 0.003).

Arterial and venous mixed PO~2~ and saturation were measured on blood samples, capillary saturation was assumed to be 100%, while alveolar PO~2~ was calculated as (P~bar~-47)× FiO~2~-PaCO~2~/R, where R = 0.8.

Study protocol
--------------

The protocol was single blinded: the patient breathed through a face mask (oxygen or oxygen + INO) and received an infusion (saline or dobutamine) throughout the study.

Measurements were started after 20 min of quiet rest in order to reach hemodynamic stability. A complete hemodynamic profile was taken before each drug administration (baseline 1, baseline 2, baseline 3), during inhalation of nitric oxide (40 ppm for 10 min), dobutamine (10 μg/kg/min for 10 min), and a combination of all the above. All tests were performed while patients were breathing 100% O~2~ via a face mask, in order to measure shunt.

Nitric oxide was obtained from a stock tank containing 500 ppm of nitric oxide in N~2~ and its administration was controlled using two electrochemical cell monitors Politron NO and NO~2~ (Drager; Lubeck, Germany) for INO and NO~2~ produced. Inspired O~2~ concentration was measured through a connection to a gas-analyzer (Capnomac-Datex; Helsinki, Finland). The sequence of drug challenge (INO, INO + dobut-amine, dobutamine; or dobutamine, INO + dobutamine, INO) was chosen randomly and each treatment started after hemodynamic values returned to the baseline level (± 5%).

Statistical analysis
--------------------

Data are reported as means ± standard deviation (SD). For the sake of clarity the baseline column in the tables reflects the mean of the three baselines prior to each drug challenge.

Comparison between each baseline and drug challenge was made by a paired *t*-test. The effects of the various treatments were compared by using one-way analysis of variance with multiple dependent measures. If a significant difference was found, a Duncan\'s multiple range test was used to determine the statistical significance among treatments. A level of *P* \< 0.05 was considered significant.

Results
=======

Inhaled nitric oxide challenge
------------------------------

Taking the whole population into consideration, INO caused a slight decrease in MPAP, PVRI, and TPG without significant modifications in the other hemodynamic parameters (Table [2](#T2){ref-type="table"}). These modifications were accompanied by a striking increase in PaO~2~ and a significant reduction in venous admixture effect.

###### 

Hemodynamic and gas exchange response to inhaled nitric oxide (INO), dobutamine, and to dobutamine plus INO in all patients. The baseline values presented are the means of the three baseline studies assessed before each challenge

                               Baseline     INO               Dobutamine         INO+Dobutamine
  ---------------------------- ------------ ----------------- ------------------ ------------------
  Cardiac index (l/min/m^2^)   3.2 ± 1.2    3.2 ± 1.2         4.7 ± 1.2^\*\*^    4.4 ± 1.2^\*\*^
  Heart rate (beats/min)       87 ± 18      86 ± 17           113 ± 18^\*\*^     109 ± 19^\*\*^
  SVI (ml/m^2^)                36 ± 10      37 ± 9            44 ± 16^\*\*^      41 ± 11^\*\*^
  CVP (mmHg)                   2.5 ± 2.8    3.1 ± 3.1         2.4 ± 2.5          2.7 ± 2.9
  MPAP (mmHg)                  26 ± 10      24 ± 9^\*\*^      31 ± 15^\*^        27 ± 12
  PAOP (mmHg)                  7 ± 3        7.4 ± 4           8 ± 4              7 ± 3
  MPAP-PAOP (mmHg)             19 ± 10      17 ± 9^\*\*^      23 ± 14            20 ± 11
  PVRI (dyne/s/cm^5^/m^2^)     535 ± 285    477 ± 293^\*^     441 ± 331          416 ± 265^\*\*^
  MAP (mmHg)                   86 ± 11      87 ± 10           86 ± 10            85 ± 10
  SVRI (dyne/s/cm^5^/m^2^)     2363 ± 764   2348 ± 786        1346 ± 243^\*\*^   1614 ± 439^\*\*^
  *Q*~s~/*Q*~t~ (%)            23 ± 5       20 ± 5^\*^        26 ± 5^\*\*^       25 ± 7
  PaO~2~/FiO~2~ (mmHg)         327 ± 90     418 ± 104^\*\*^   296 ± 90^\*^       390 ± 111^\*\*^
  PaCO~2~ (mmHg)               51 ± 12      52 ± 12           51 ± 13            50 ± 13

^\*^*P* \< 0.05; ^\*\*^*P* \< 0.01. CVP, cardiovenous pressure; INO, inhaled nitric oxide; MAP, mean systemic arterial pressure; MPAP, mean pulmonary arterial pressure; PAOP, pulmonary artery occluded pressure; PVRI, pulmonary vascular resistance index; SVI, systemic vascular index; SVRI, systemic vascular resistance index.

The same trend was also observed when each disease group was analyzed separately (Tables [3](#T3){ref-type="table"},[4](#T4){ref-type="table"},[5](#T5){ref-type="table"}).

###### 

Hemodynamic and gas exchange response to inhaled nitric oxide (INO), dobutamine, and INO plus dobutamine in bronchiectasis (9 patients)

                               Baseline 1   INO          Dobutamine   INO+Dobutamine
  ---------------------------- ------------ ------------ ------------ ----------------
  Cardiac index (l/min/m^2^)   3.9 ± 1.9    3.8 ± 1.5    5.6 ± 1.4    4.5 ± 0.3
  Heart rate (beats/min)       87 ± 17      85 ± 12      115 ± 25     114 ± 23^\*^
  SVI (ml/m^2^)                43 ± 15      43 ± 13      53 ± 27      42 ± 12
  CVP (mmHg)                   3.2 ± 2.8    4 ± 3        3.2 ± 2.7    3.2 ± 3.9
  MPAP (mmHg)                  33 ± 16      28 ± 14      37 ± 17      36 ± 17
  PAOP (mmHg)                  9.4 ± 2      7.8 ± 1      12.5 ± 5     9.2 ± 3.3
  MPAP-PAOP (mmHg)             24 ± 15      20 ± 14      24 ± 17      27 ± 18
  PVRI (dyne/s/cm^5^/m^2^)     781 ± 424    662 ± 355    569 ± 321    641 ± 335^\*^
  MAP (mmHg)                   86 ± 10      88 ± 9       90 ± 14      79 ± 11
  SVRI (dyne/s/cm^5^/m^2^)     1919 ± 684   1974 ± 712   1272 ± 256   1391 ± 237^\*^
  *Q*~s~/*Q*~t~ (%)            19 ± 5       11 ± 4^\*^   24 ± 7       15 ± 12
  PaO~2~/FiO~2~ (mmHg)         366 ± 113    448 ± 92     344 ± 95     435 ± 115
  PaCO~2~ (mmHg)               51 ± 20      52 ± 23      53 ± 24      56 ± 23

^\*^*P* \< 0.05; ^\*\*^*P* \< 0.01. CVP, cardiovenous pressure; INO, inhaled nitric oxide; MAP, mean systemic arterial pressure; MPAP, mean pulmonary arterial pressure; PAOP, pulmonary artery occluded pressure; PVRI, pulmonary vascular resistance index; SVI, systemic vascular index; SVRI, systemic vascular resistance index.

###### 

Hemodynamic and gas exchange response to inhaled nitric oxide (INO), dobutamine, and INO plus dobutamine in cystic fibrosis (8 patients)

                               Baseline     INO            Dobutamine     INO+Dobutamine
  ---------------------------- ------------ -------------- -------------- ------------------
  Cardiac index (l/min/m^2^)   3.6 ± 0.6    3.6 ± 0.5      5.1± 0.6       4.7± 0.5^\*\*^
  Heart rate (beats/min)       90 ± 26      90 ± 25        102 ± 22       104 ± 18
  SVI (ml/m^2^)                43 ± 12      43 ± 10        52 ± 10        47 ± 7
  CVP (mmHg)                   1.4 ± 1.9    1.6 ± 2.1      1.9 ± 2.4      1.4 ± 2
  MPAP (mmHg)                  24 ± 4       22 ± 3         26 ± 5         24 ± 3
  PAOP (mmHg)                  5.7 ± 2.7    6.5 ± 3.5      6.2 ± 3.3      5.6 ± 2.6
  MPAP-PAOP (mmHg)             18 ± 2       16 ± 2^\*^     20 ± 2         18 ± 3
  PVRI (dyne/s/cm^5^/m^2^)     591 ± 148    548 ± 140      448 ± 96^\*^   460 ± 98^\*^
  MAP (mmHg)                   83 ± 15      83 ± 11        87 ± 13        89 ± 13
  SVRI (dyne/s/cm^5^/m^2^)     1826 ± 261   1825 ± 230     1371 ± 193     1495 ± 197^\*\*^
  *Q*~s~/*Q*~t~ (%)            20 ± 7       17 ± 4         30 ± 6^\*^     22 ± 5
  PaO~2~/FiO~2~ (mmHg)         276 ± 56     350 ± 48^\*^   260 ± 56       319 ± 65
  PaCO~2~ (mmHg)               54 ± 11      55 ± 11        54 ± 12        53 ± 12

^\*^*P* \< 0.05; ^\*\*^*P* \< 0.01. CVP, cardiovenous pressure; INO, inhaled nitric oxide; MAP, mean systemic arterial pressure; MPAP, mean pulmonary arterial pressure; PAOP, pulmonary artery occluded pressure; PVRI, pulmonary vascular resistance index; SVI, systemic vascular index; SVRI, systemic vascular resistance index.

###### 

Hemodynamic and gas exchange response to inhaled nitric oxide (INO), dobutamine, and INO plus dobutamine in severe chronic obstructive pulmonary disease (COPD) (11 patients)

                               Baseline     INO             Dobutamine      INO+Dobutamine
  ---------------------------- ------------ --------------- --------------- ------------------
  Cardiac index (l/min/m^2^)   3.2 ± 1.9    3.2 ± 2.3       5.0 ± 2.7       4.7 ± 2.4^\*\*^
  Heart rate (beats/min)       83 ± 28      83 ± 30         104 ± 28        101 ± 29^\*^
  SVI (ml/m^2^)                38 ± 11      39 ± 13         49 ± 18         47 ± 19
  CVP (mmHg)                   2.5 ± 3      2.5 ± 3.1       2.0 ± 1.8       2.0 ± 2.0
  MPAP (mmHg)                  23 ± 7       21 ± 7          25 ± 8          24 ± 9
  PAOP (mmHg)                  6.6 ± 4.5    6.0 ± 4.9       5.3 ± 4.7       5.0 ± 4.0
  MPAP-PAOP (mmHg)             16 ± 8       15 ± 6          19 ± 7^\*^      19 ± 9
  PVRI (dyne/s/cm^5^/m^2^)     671 ± 277    601 ± 247       471 ± 262^\*^   492 ± 300^\*^
  MAP (mmHg)                   87 ± 12      89 ± 11         91 ± 9          93 ± 12
  SVRI (dyne/s/cm^5^/m^2^)     2524 ± 873   2625 ± 1012     1654 ± 541      1824 ± 683^\*\*^
  *Q*~s~/*Q*~t~ (%)            23 ± 11      15 ± 6          28 ± 10^\*^     17 ± 5
  PaO~2~/FiO~2~ (mmHg)         322 ± 115    442 ± 103^\*^   310 ± 93        419 ± 90^\*^
  PaCO~2~ (mmHg)               45 ± 11      44 ± 11         43 ± 11         45 ± 13

^\*^*P* \< 0.05; ^\*\*^*P* \< 0.01. CVP, cardiovenous pressure; INO, inhaled nitric oxide; MAP, mean systemic arterial pressure; MPAP, mean pulmonary arterial pressure; PAOP, pulmonary artery occluded pressure; PVRI, pulmonary vascular resistance index; SVI, systemic vascular index; SVRI, systemic vascular resistance index.

Dobutamine challenge
--------------------

Dobutamine infusion caused an increase in cardiac index, heart rate, systemic vascular index (SVI), and MPAP with no change in CVP, PAOP, and MAP. PVRI and SVRI decreased significantly (Table [2](#T2){ref-type="table"}). There was also a decrease in PaO~2~ and a significant increase in *Q*~s~/*Q*~t~, with no change in PaCO~2~.

The same trend was also observed when each disease group was analyzed separately (Tables [3](#T3){ref-type="table"},[4](#T4){ref-type="table"},[5](#T5){ref-type="table"}).

Inhaled nitric oxide plus dobutamine challenge
----------------------------------------------

The combination of INO and dobutamine caused a significant increase in cardiac index, heart rate and SVI, without modifying either MPAP or MAP, as a result of a significant fall in pulmonary and systemic vascular resistance. CVP and PAOP had no significant change. There was a significant increase in PaO~2~ and slight but not significant increase in *Q*~s~/*Q*~t~ with no change in PaCO~2~. The same trend was also observed when each disease group was analyzed separately (Tables [3](#T3){ref-type="table"},[4](#T4){ref-type="table"},[5](#T5){ref-type="table"}).

Comparison of treatments
------------------------

Only INO caused a light but statistically significant reduction of MPAP and TPG without changes in cardiac index or SVRI. On the other hand, only dobutamine and the combination of the two drugs elicited an increase in cardiac index with a reduction in SVRI.

In order to analyze pulmonary hemodynamic response, we plotted the modification of TPG in function of pulmonary flow on a pressure--flow chart with isoresistance lines passing through the origin of the axis. Three different patterns were observed: INO caused a downward shift through lower isore-sistance lines; dobutamine caused a shift right and upwards, almost parallel to the isoresistance line representing the flow-pressure relationship for a vascular resistance equal to 300 dynes/s/cm^5^; and the combined treatment showed an intermediate reaction with a rightward shift (Figure [1](#F1){ref-type="fig"}).

![Flow-pressure diagram showing the difference of MPAP and PAOP (MPAP-PAOP) and cardiac index. The dashed lines indicate the isoresistance lines from 600 to 300 dyne/s/cm^5^. INO, inhaled nitric oxide; MPAP, mean pulmonary arterial pressure; PAOP, pulmonary artery occluded pressure.](CC-5-6-355-1){#F1}

Arterial blood gases analysis showed no change in arterial CO~2~ tension during the administration of the three regimens. On the other hand, PaO~2~ increased with INO therapy and the combined therapy with dobutamine and INO, while it decreased when dobutamine was used by itself.

This behavior was congruent with the reduction in *Q*~s~/*Q*~t~ during treatment with INO and the increase in *Q*~s~/*Q*~t~ during treatment with dobutamine alone. During therapy with the combination of the two drugs (INO + dobutamine) *Q*~s~/*Q*~t~ increased slightly, thus the increase in PaO~2~ is mainly a result of an increase in mixed venous oxygen saturation.

Discussion
==========

Inhaled nitric oxide challenge
------------------------------

As was expected, our study confirms that INO has a selective vasodilator effect on pulmonary circulation in patients with severe airway disease. Treatment with INO slightly reduced MPAP, PVRI, and TPG, with no changes in cardiac index, MAP and SVRI. Its actual vasodilator effect is documented by the reduction in TPG, and a downward shift of pulmonary pressure--flow relationship. The magnitude of MPAP reduction in our study population was smaller than that reported in other studies \[[@B10],[@B11]\]. These differences can be reconciled considering that in our study patients were on 100% oxygen and, possibly, with a complete abolition of hypoxic vasocon-striction. Moreover, the severity of lung disease and the variability in vascular responsiveness can explain this difference.

The relevant finding was that the vasodilator effect of INO was accompanied by an improvement in arterial oxygenation. Previous studies demonstrated that INO may improve or worsen arterial oxygenation in patients with COPD. In severe COPD, Barbera et al. \[[@B11]\] demonstrated that INO, when administered in room air, impairs pulmonary alveolar ventilation/capillary flow ratio (*V*~A~/*Q*~C~) and slightly reduces arterial oxygenation, while Moinard et al. \[[@B12]\] observed no change in PaO~2~.

On the other hand, Yoshida et al. \[[@B13]\] and Germann *et al*. \[[@B14]\] observed an increase in PaO~2~ and a reduction of pulmonary venous admixture using low-dose nitric oxide (5--20 ppm) in combination with oxygen.

Our data are in agreement with those two studies. By combining INO with oxygen, it is conceivable that, in alveolar units with low *V*~A~/*Q*~c~, the increase in alveolar PO2, resulting from the high FiO~2~,matched the improved alveolar perfusion, minimizing the worsening of pulmonary *V*~A~/*Q*~c~ seen during the administration of INO alone \[[@B13]\].

Dobutamine challenge
--------------------

The effect of dobutamine on pulmonary circulation has not been extensively assessed in patients with mild to moderate pulmonary hypertension. In two small studies, dobutamine increased cardiac output and improved oxygen transport and oxygenation in patients with massive pulmonary embolism \[[@B15],[@B16]\]. Experimental studies in dogs with pulmonary hypertension secondary to embolization of the pulmonary vascular bed demonstrated that dobutamine increases the cardiac index and decreases calculated PVRI. However, pulmonary pressure--flow plots suggest that these findings are not a result of vasodilation \[[@B17]\].

In the study reported here, dobutamine infusion showed similar hemodynamic effects. Dobutamine caused a significant increase in the cardiac index, with a concomitant reduction in SVRI and PVRI. The reduction in PVRI was not proportional to the increase in the cardiac index, leading to an increase in MPAP. This behavior could be explained mainly as a recruitment of vessels rather than as a real vasodilator effect. It is noteworthy that the pressure--flow plot showed a slope very close to that of the isoresistance line equal to 300 dynes/s/cm^5^. If we accept the viscoelastic model of the pulmonary circulation, this is the case in which the vascular closing pressure is higher than PAOP and should be considered as the effective outflow pressure for the pulmonary vascular bed. Considering PAOP as outflow pressure, the transpulmonary gradient is overestimated by the calculation of pulmonary vascular resistance, and it becomes flow-dependent even if no vasodilation has occurred \[[@B18]\]. The prevalent role of vascular recruitment as a mechanism in pulmonary vascular resistance reduction during dobutamine therapy is supported by the concomitant reduction in arterial oxygenation and the increase in pulmonary *Q*~s~/*Q*~t~. This strongly suggests aworsening of regional *V*~A~/*Q*~C~ as a result of an increased perfusion of poorly or unventilated areas of the lung.

Inhaled nitric oxide plus dobutamine challenge
----------------------------------------------

To our knowledge, the interaction of INO and dobutamine on the pulmonary circulation has not been previously reported. Our results indicate that the combined use of both drugs produces a complementary effect which improves circulation and gas exchange. The combination of both drugs causes an increase in cardiac index but no change in MPAP. This suggests that the increase in the cardiac index induced by dobut-amine is counterbalanced by the concomitant actual pulmonary vasodilation induced by NO. This interpretation is supported further by analysis of the pulmonary pressure--flow relationship: during administration of the combination of the two drugs the line has a slope intermediate between that of dobutamine and INO when each is given alone.

The other relevant finding is that the favorable hemodynamic effects are not associated with a deterioration in gas exchange, probably because of the vasodilatory effect of INO, which is evident in well-ventilated areas of the lung.

In accordance with the results of the present study, the algorithm reported in Figure [2](#F2){ref-type="fig"} may be suggested as a guide in the management of patients with mild to moderate secondary pulmonary hypertension in cases of acute cardiorespiratory decompensation.

![Decisional algorithm according to the different values of cardic index and the different values of MPAP and PAOP (MPAP-PAOP) in cases of acute cardiac decompensation. =, low TPG; ↑, moderate TPG; ↑↑, high TPG. INO, inhaled nitric oxide; MPAP, mean pulmonary arterial pressure; PAOP, pulmonary artery occluded pressure; TPG, transpulmonary gradient.](CC-5-6-355-2){#F2}

Inhaled nitric oxide and dobutamine have significant hemody-namic effects in mild to moderate pulmonary hypertension. Nitric oxide has a real, selective pulmonary vasodilating effect accompanied by an improvement in arterial oxygenation, but no change in cardiac output. Dobutamine, on the other hand, increases pulmonary blood flow in the face of increasing mean pulmonary pressure and a decrease in PaO~2~. The combination of the two drugs shows more favorable effects. In fact, the increase in cardiac index is associated with no modification in MPAP, and an increase in PaO~2~. These data show that INO and dobutamine have a complementary beneficial action, further studies are warranted to examine their use as a therapeutic option in right ventricular failure during exacerbations of chronic pulmonary disease.

Study limitation
----------------

Patients with different diseases but who shared a common physiopathology (severe airways disease) were included in this study. Although the small number of patients in each group did not allow a direct statistical comparison to be drawn between them, the results are consistent.

All patients were studied while breathing 100% O~2~ in an attempt to measure the true shunt. Considering the high value of shunt in our population (23%) compared to that reported in the literature \[[@B19]\], it is possible that the severity of airways impairment prevented a complete alveolar denitrogenification leading to the measurement of a venous mixture effect.

The use of low-dose dobutamine as inotropic support in right ventricular failure is a regular practice in an intensive care setting or in the operating room. It could be argued that its use in patients with cor pulmonale could have detrimental effects, but in the short term the beneficial hemodynamic effects (increased cardiac output and systemic oxygen delivery) usually outweigh the negative effects (increased right ventricular work and oxygen demand).
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